Introduction {#s1}
============

Recent studies have begun to unravel the mechanisms linking the host inflammatory response to tumor growth, invasion and metastasis in non-small cell lung cancer (NSCLC) \[[@R01]\].

It has been also recognized that systemic inflammatory responses play an important role in the development of tumor, enhancement of local immunosuppression, thereby worsening the prognosis of the patients \[[@R02]-[@R07]\]. Based on this relationship between inflammation and cancer progression, several inflammation-based scores, including Glasgow prognostic score (GPS) \[[@R02]\], neutrophil-to-lymphocyte ratio (NLR) \[[@R03]\], platelet-to-lymphocyte ratio (PLR) \[[@R04]\], prognostic nutritional index (PNI) \[[@R05]\], systemic immune-inflammation index (SII) \[[@R06]\] and advance lung cancer inflammation index (ALI) \[[@R07]\], have been demonstrated to have prognostic value in NSCLC.

In other malignancies, some previous studies compared the prognostic value of selected inflammation-based scores \[[@R08]-[@R11]\]. To our knowledge, however, there are no studies elucidating which of these prognostic scores is more suitable in predicting outcomes in patients with NSCLC undergoing surgery. Therefore, the aim of this study was to compare the prognostic value of these inflammation-based scores in patients undergoing potentially curative resection for NSCLC.

Patients and Methods {#s2}
====================

This retrospective study examined the records of a sequential series of 381 patients with NSCLC who received complete resection and fill the inclusion criteria between January 2008 and December 2012 in our hospital. There were 173 men and 168 women (median age: 69 years old). The inclusion criteria were as following: histologically confirmed NSCLC and complete clinical, laboratory, imaging and follow-up data. The exclusion criteria included: preoperative chemotherapy/radiotherapy or died perioperative period, clinical evidence of infection or other bone marrow, hematological or autoimmune disease. This retrospective study was approved by Medical Ethics Committee of our hospital (O-0296). Complete blood count and routine biochemistry test, including serum C-reactive protein (CRP), serum albumin, serum carcinoembryonic antigen (CEA) and serum cytokeratin 19 fragments (CYFRA21-1), of each patient was applied 1 week before surgery. The GPS, NLR, PLR, PNI, SII and ALI were constructed as described in [Table 1](#T1){ref-type="table"}. Cut-off values of NLR, PLR and PNI were determined according to previous reports \[[@R03]-[@R05]\]. The optimal cut-off value of SII and ALI for overall cancer-specific survival was determined by Cutoff Finder (<http://molpath.charite.de/cutoff>) \[[@R12]\].

###### Inflammation-Based Prognostic Scores

                                                          Score
  ------------------------------------------------------- -------
  Glasgow Prognostic Score (GPS)                          
    C-reactive protein ≤ 10 mg/L and albumin ≥ 35 g/L     0
    C-reactive protein ≤ 10 mg/L and albumin \< 35 g/L    1
    C-reactive protein \> 10 mg/L and albumin ≥ 35 g/L    1
    C-reactive protein \> 10 mg/L and albumin \< 35 g/L   2
  Neutrophil lymphocyte ratio (NLR)                       
    Neutrophil count/lymphocyte count \< 5:1              Low
    Neutrophil count/lymphocyte count ≥ 5:1               High
  Platelet lymphocyte ratio (PLR)                         
    Platelet count/lymphocyte count \< 150:1              0
    Platelet count/lymphocyte count 150 - 300             1
    Platelet count/lymphocyte count \> 300:1              2
  Prognostic nutritional index (PNI)                      
    Albumin (g/L) + 5 × total lymphocyte count ≥ 45       0
    Albumin (g/L) + 5 × total lymphocyte count \< 45      1
  Systemic immune-inflammation index (SII)                
    Platelet count × NLR \< cut-off value                 Low
    Platelet count × NLR ≥ cut-off value                  High
  Advance lung cancer inflammation index (ALI)            
    Body mass index × albumin/NLR ≥ cut-off value         Low
    Body mass index × albumin/NLR \< cut-off value        High

Association between categorical variables was assessed using the Fisher's exact test. Cancer-specific survival curves were plotted using the Kaplan-Meier method, with comparisons between groups performed using the log-rank test. A receiver operating characteristics (ROC) curve was generated and the area under the curve (AUC) was calculated to evaluate the discriminatory ability of each scoring systems. Univariate and multivariate analyses were performed for prognostic factors using the Cox proportional hazards model. Variables that proved to be significant on univariate analysis were subsequently subjected to a multivariate Cox proportional hazards model. Hazard ratios (HRs) estimated using the Cox analysis are reported as relative risks with corresponding 95% confidence intervals (CIs). Statistical analyses were performed using JMP (SAS Institute Inc., Cary, NC, USA). Differences were considered statistically significant when P \< 0.05.

Results {#s3}
=======

Analysis using the Cutoff Finder showed the recommended cut-off values of SII and ALI for evaluating cancer-specific survival were 471.2 × 10^9^/L and 37.66, respectively.

The relationships between clinical characteristics and each inflammation-based score were shown in [Table 2](#T2){ref-type="table"}. There is a trend towards an association between these inflammation-based scores and gender, pStage and pN status. However, the results of these scores were not always identical each other.

###### The Relationships Between Clinical Characteristics and Each Inflammation-Based Score

                    GPS              NLR   SII                                                 
  ----------------- ---------------- ----- ----- ---- --------- ----- ---- ------- ----- ----- ----------
  Age (years old)   \< 65            68    31    7    0.063     98    8    0.222   62    44    0.276
                    ≥ 65             123   81    31             225   10           152   83    
  Gender            Male             83    65    25   0.007     158   15   0.003   93    80    0.001
                    Female           108   47    13             165   3            121   47    
  Smoking           Never            109   40    9    \<0.001   154   4    0.029   114   44    0.001
                    Current/former   82    72    29             169   14           100   83    
  Histology         Adeno            163   81    24   0.002     258   10   0.024   182   86    \< 0.001
                    Others           28    31    14             65    8            32    41    
  pStage            I                150   91    24   0.081     256   9    0.008   178   87    \< 0.001
                    II - III         41    21    14             67    9            36    40    
  pT status         pT1              136   82    17   0.004     227   8    0.027   157   78    0.022
                    pT2-3            55    30    21             96    10           57    49    
  pN status         pN0              163   100   29   0.162     281   11   0.008   192   100   0.006
                    pN1-2            28    12    9              42    7            22    27    
  CEA               Normal           146   84    24   0.250     241   13   0.822   159   95    0.918
                    High             45    28    14             82    5            55    32    
  CYFRA             Normal           166   91    26   0.026     272   11   0.023   181   102   0.314
                    High             25    21    12             51    7            33    25    

              PLR              PNI   ALI                                              
  ----------- ---------------- ----- ----- --- ------- ----- ----- ------- ---- ----- -------
  Age         \< 65            62    40    4   0.084   82    24    0.001   37   69    0.941
              ≥ 65             166   61    8           138   97            83   152   
  Gender      Male             106   58    9   0.040   109   64    0.554   73   100   0.006
              Female           122   43    3           111   57            47   121   
  Smoking     Never            114   41    3   0.086   105   53    0.486   43   115   0.004
              Current/former   114   60    9           115   68            77   106   
  Histology   Adeno            185   75    8   0.235   175   93    0.565   82   186   0.001
              Others           43    26    4           45    28            38   35    
  pStage      I                186   73    6   0.018   170   95    0.792   83   182   0.006
              II - III         42    28    6           50    26            37   39    
  pT status   pT1              162   68    5   0.111   157   78    0.190   76   159   0.103
              pT2-3            66    33    7           63    43            44   62    
  pN status   pN0              203   81    8   0.027   191   101   0.403   95   197   0.014
              pN1-2            25    20    4           29    20            25   24    
  CEA         Normal           171   74    9   0.946   169   85    0.186   87   167   0.537
              High             57    27    3           51    36            33   54    
  CYFRA       Normal           194   80    9   0.334   190   93    0.028   89   194   0.002
              High             34    21    3           30    28            31   27    

GPS: Glasgow prognostic score; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index; ALI: advance lung cancer inflammation index; CEA: carcinoembryonic antigen; CYFRA21-1: cytokeratin 19 fragments.

The relationship between the inflammation-based prognostic scores and cancer-specific overall survival is shown in [Figure 1](#F1){ref-type="fig"}. Based on total number of patients, the 5-year cancer-specific overall survival of patients with GPS 0, low NLR, PLR 0, PNI 1, low SII and high ALI were 83.19%, 76.75%, 80.92%, 79.01%, 83.61% and 84.20%, respectively. On the other hand, those of patients with GPS 1-2, high NLR, PLR 1-2, PNI 0, high SII and low ALI were 64.53%, 40.18%, 62.89%, 67.40%, 860.39% and 57.61%, respectively. All of GPS (P \< 0.001), NLR (P \< 0.001), PLR (P \< 0.001), PNI (P = 0.014), SII (P \< 0.001) and ALI (P \< 0.001) were associated with a cancer-specific overall survival.

![(a) Overall postoperative cancer-specific survival of patients based on Glasgow prognostic score (GPS, P \< 0.001); (b) neutrophil-to-lymphocyte ratio (NLR, P \< 0.001); (c) platelet-to-lymphocyte ratio (PLR, P \< 0.001); (d) prognostic nutritional index (PNI, P = 0.014); (e) systemic immune-inflammation index (SII, P \< 0.001); (f) advance lung cancer inflammation index (ALI, P \< 0.001).](wjon-09-085-g001){#F1}

Comparison of the AUCs for cancer-specific overall survival prediction between these inflammation-based prognostic scores was shown in [Figure 2](#F2){ref-type="fig"}. The AUCs of GPS, NLR, PLR, PNI, SII and ALI were 0.642, 0.643, 0.590, 0.608, 0.623 and 0.681, respectively. ALI consistently had a higher AUC value in comparison with other inflammation-based scores.

![Comparison of the area under the receiver operating characteristics (ROC) for outcome prediction between the inflammation-based prognostic scores.](wjon-09-085-g002){#F2}

The univariate analysis showed that gender, smoking status, histology, pT status, pN status, serum CEA level, serum CYFRA21-1 level, serum CRP level, GPS, NLR, PLR, PNI, SII and ALI were significant association with the 5-year cancer-specific survival ([Table 3](#T3){ref-type="table"}). All 13 clinicopathological characteristics and inflammation-based scores were further investigated in multivariate analysis. As shown in [Table 3](#T3){ref-type="table"}, gender (P = 0.003), histology (P = 0.001), pN status (P = 0.001), serum CEA level (P = 0.001), GPS (P = 0.009) and ALI (P = 0.026) were independent factors in predicting overall postoperative cancer specific survival, while others were not.

###### Univariate and Multivariate Analyses

                   Univariate   Multivariate                                           
  ---------------- ------------ -------------- ------- ------- ------- ------- ------- -------
  Age              0.755        0.235          0.461   1.193                           
  Gender           0.329        \< 0.001       0.204   0.514   0.367   0.003   0.183   0.717
  Smoking status   0.349        \< 0.001       0.215   0.549   0.696   0.323   0.344   1.435
  Histology        0.250        \< 0.001       0.165   0.382   0.439   0.001   0.271   0.715
  pT status        0.450        \< 0.001       0.298   0.683   0.958   0.866   0.590   1.580
  pN status        0.330        \< 0.001       0.211   0.534   0.409   0.002   0.242   0.704
  CEA              0.382        \< 0.001       0.252   0.586   0.446   0.001   0.287   0.702
  CYFRA21-1        0.353        \< 0.001       0.229   0.556   0.835   0.502   0.501   1.428
  GPS              0.409        \< 0.001       0.265   0.622   0.499   0.009   0.296   0.838
  NLR              0.309        0.003          0.168   0.635   0.963   0.922   0.472   2.139
  PLR              0.462        \< 0.001       0.306   0.698   0.834   0.532   0.471   1.473
  PNI              0.599        0.017          0.396   0.910   0.772   0.346   0.449   1.323
  SII              0.368        \< 0.001       0.241   0.556   0.927   0.841   0.444   1.920
  ALI              0.312        \< 0.001       0.204   0.473   0.444   0.026   0.217   0.907

GPS: Glasgow prognostic score; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index; ALI: advance lung cancer inflammation index; CEA: carcinoembryonic antigen; CYFRA21-1: cytokeratin 19 fragments; CI: confidence interval.

Discussion {#s4}
==========

The univariate analysis in this study demonstrated that the GPS, NLR, PLR, PNI, SII and ALI were significantly associated with overall cancer-specific survival of NSCLC patients who underwent potentially curative resection. However, the multivariate analysis showed that GPS and ALI were independently associated with overall cancer-specific survival. Moreover, the AUC analysis has shown that ALI was superior to other inflammation-based prognostic scores in terms of predictive accuracy in patients undergoing potentially curative resection for NSCLC. To our knowledge, this was the first report investigating the comparison of inflammation-based scores in operable patients with NSCLC, and showing GPS and ALI to be superior to other inflammation-based prognostic scores for the prediction of prognosis in patients with operable NSCLC.

Inflammation in the tumor microenvironment contributes substantially to tumor proliferation, angiogenesis, invasion, metastasis and survival, suggesting that the systemic inflammatory factors may act as the prognostic markers in NSCLC \[[@R01]\]. CRP is a non-specific inflammatory acute-phase protein, and an elevated serum CRP level has been reported as an indicator of unfavorable prognosis in patients with NSCLC \[[@R13]\]. Among inflammation-based scores examined in this study, GPS was only based on CRP. Therefore, the superiority of GPS in multivariate analysis might be due to the prognostic power of CRP, at least in part. GPS was defined as the combination of CRP and albumin \[[@R02]\]. Nutritional status of cancer patients, commonly reflected by serum albumin, is also a determinant of survival in NSCLC \[[@R14]\]. Among inflammation-based scores examined in this study, in addition to GPS, PNI and ALI were defined to be based on albumin and other factors. Therefore, the prognostic power of albumin might be offset in multivariate analysis. Another factor to evaluate the nutritional status was body mass index (BMI). A meta-analysis showed that BMI had an inverse association with risk of cancer-specific survival in NSCLC \[[@R15]\]. Among inflammation-based scores examined, only ALI was based on BMI. Therefore, there is a possibility that the superiority of ALI in multivariate analysis and the AUC of ROC curve is also due to the prognostic power of BMI in part.

NLR has been reported to be a useful biomarker to measure the inflammatory status of immune system \[[@R03]\]. The neutrophil is known to be able to aid the proliferation and survival of malignant cells, promote angiogenesis and metastasis \[[@R03]\]. Conversely, lymphocytes suppress tumor growth and invasion through their cytolytic activity \[[@R03]\]. Taken together, patients with high NLR have a relative lymphocytopaenia, and, as a result, may exhibit a poorer immune response to malignancy, thereby worsening their prognosis \[[@R03]\]. Among inflammation-based scores examined, in addition to NLR, SII and ALI were also based on NLR. Furthermore, PLR and PNI were defined as the combination of lymphocyte count and other factors. Therefore, there is a possibility that the prognostic power of NLR was offset in multivariate analysis.

Several limitations of this study should be acknowledged. First, the study involved a small sample size and single-center design. Second, this study's retrospective design renders it susceptible to selection and analytical biases. Nevertheless, our data indicated that preoperative GPS and ALI might represent independent prognostic factors in patients with resectable NSCLC. GPS and ALI are simple, inexpensive and they do not require extra equipment. Therefore, GPS and ALI should be taken into consideration in the therapeutic program for resectable NSCLC.

In conclusion, to the best of our knowledge, this is the first study to demonstrate that GPS and ALI appear to be superior to other inflammation-based prognostic scores in patients undergoing potentially curative resection for NSCLC.
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